As chief medical officer, Global Drug Development, Samit Hirawat, M.D., oversees late-stage drug development across all therapeutic areas at Bristol Myers Squibb (BMS), including the design and operation of clinical trials. A physician by training, Hirawat specialized in oncology and clinical research before transitioning to drug development. He joined BMS in 2019 after serving as executive vice president and head of Oncology Global Development for Novartis. Hirawat recently reflected on the progress of the company’s R&D pipeline, the impact COVID-19 has had on clinical trials and the completion of his first year at BMS.
External News Article:
Add reference to external site news article